Die Beteiligung der Transmembranproteine EMMPRIN und Connexin 43 an der Epithelial-Mesenchymalen Transition (EMT) und Metastasierung im oralen Plattenepithelkarzinom
by Lucas Fischer
Date of Examination:2024-12-17
Date of issue:2024-12-02
Advisor:Prof. Dr. Dr. Phillipp Brockmeyer
Referee:Prof. Dr. Dr. Phillipp Brockmeyer
Referee:Prof. Dr. Felix Bremmer
Files in this item
Name:Lucas_Fischer_eDiss.pdf
Size:1.79Mb
Format:PDF
Abstract
English
Metastasis is a major challenge in the progression of oral squamous cell carcinoma (OSCC) and is closely related to epithelial-mesenchymal transition (EMT) of tumor cells. In the present study, the expression profiles of EMMPRIN and connexin 43 together with the known EMT markers E-cadherin and vimentin were evaluated by immunohistochemistry in tissue samples from 24 OSCC patients throughout the metastatic process. For this purpose, the expression profiles in different regions of interest (ROIs), healthy oral mucosa, the center of the primary OSCC, the invasion front, and the corresponding cervical lymph node metastases. In addition, the prognostic effect was evaluated both as a combined marker system and individually for the clinical endpoints of disease-free survival (DFS) and overall survival (OS). Significant changes in the expression profiles of the different marker proteins were observed between the different ROIs. The results of multivariate Cox regression analysis showed a significant effect of increased EMMPRIN expression towards the invasion front on DFS and OS. In addition, the combined predictive analysis showed a significant predictive value of the marker system for disease-free survival and overall survival. The results of this study demonstrate that a combined biomarker system can reliably predict overall and disease-free survival in patients. In particular, changes in EMMPRIN expression were shown to have the greatest prognostic significance, suggesting a potential therapeutic target for antimetastatic interventions.
Keywords: emmprin; connexin 43; oral squamous cell carcinoma; e-cadherin; vimentin